Meeting Minutes: Drug Formulary Committee

Date & Time: March 4, 2020; 5:30-9 PM
Minutes prepared by: Justin Johnson and Dave Hoang
Location: Elmer Andersen Building, Room 2370, 540 Cedar Street, St. Paul, MN 55101

Attendance

- Members in attendance: Stacey Ness, PharmD.; Margaret Artz, RPh., PhD.; Monica Brands, RPh.; Al Heaton, PharmD.; Kyle Lehenbauer, MD.; Kathryn Lombardo, MD.; Kelly Ruby, PharmD.; Stuart Williams, J.D.; Mary Mescher Benbenek, APRN, PhD.;
- Members absent: James Phillips, MD.; Ramona Powell, PharmD.; Michael Sprehe, MD.
- DHS staff present: Dave Hoang, PharmD., MBA; Chad Hope, PharmD.; Nathan Chomilo, MD.; Mary Beth Reinke, PharmD., MSA
- Others in attendance: Hind Douiki, PharmD.; Ariane Casey, PharmD.; Justin Johnson, PharmD.

Report of the Chair

- Dr. Ness presided over the meeting.

Approval of Minutes

- Minutes from the January 2020 meeting were reviewed and approved.

DHS Housekeeping

- Dr. Nathan Chomilo, MD, FAAP, our new Medical Director for the Minnesota Health Care Programs was introduced.
- It was announced this is the last meeting for Hind Douiki, PharmD. who is transitioning to another job. Justin Johnson, PharmD. will be taking over her role going forward. We wish Hind well and look forward to working with Justin.

Old Business – None

New Business
Existing Drugs for New PA

- The committee discussed the Antifungals, Topical therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Antifungals, Topical drugs remain as they have been revised.

Existing Specialty Drugs for New PA

- The committee discussed Eylea and recommended to the department by a unanimous vote to adopt the proposed criteria for Eylea with an additional bullet to read “Therapy will not be used with other ophthalmic VEGF inhibitors”.

- The committee discussed Lucentis and recommended to the department by a unanimous vote to adopt the proposed criteria for Lucentis with the addition of “Therapy will not be used with other ophthalmic VEGF inhibitors”.

New Specialty Drugs for Continued PA

- The committee discussed Beovu and recommended to the department by a unanimous vote that Beovu remain on PA with the proposed criteria.

- The committee discussed Trikafta and recommended to the department by a unanimous vote that Trikafta remain on PA with the proposed criteria, with the following changes:
  - Change the 10th bullet of the initial approval criteria to “Patient must be seen at least twice a year for the first year and once a year thereafter by a provider who is on staff at a Cystic Fibrosis (CF) Care Center accredited by the CF Foundation; AND”
  - Remove the separate transition criteria for Orkambi, and include Orkambi in the transition criteria for Kalydeco and Symdeco
  - Change the last bullet of the renewal criteria to the following “Renewal approval is for 1 year”

- The committee discussed Pretomanid and recommended to the department by a unanimous vote that Pretomanid remain on PA with the proposed criteria with the revision to change the quantity limit to 26 weeks.

- The committee discussed Reblozyl and recommended to the department by a unanimous vote that Reblozyl remain on PA with the proposed criteria.

- The committee discussed Vitrakvi and recommended to the department by a unanimous vote that Vitrakvi remain on PA with the proposed criteria.

- The committee discussed Givlaari and recommended to the department by a unanimous vote that Givlaari remain on PA with the proposed criteria.
• The committee discussed Padcev and recommended to the department by a unanimous vote that Padcev remain on PA with the proposed criteria with the following additions:
  o Female patient of child-bearing age must have a confirmed negative pregnancy test prior to therapy
  o Patient will use an effective form of contraception (i.e., females of reproductive potential should use effective contraception during treatment and for at least 2 months following the last dose and male patients with female partners of reproductive potential should use effective contraception during treatment and for at least 4 months after the last dose);

• The committee discussed Enhertu and recommended to the department by a unanimous vote that Enhertu remain on PA with the proposed criteria.

• The committee discussed Vyondys-53 and recommended to the department by a unanimous vote that Vyondys-53 remain on PA with the proposed criteria.

• The committee discussed Oxbryta and recommended to the department by a unanimous vote that Oxbryta remain on PA with the proposed criteria.

• The committee discussed Adakveo and recommended to the department by a unanimous vote that Adakveo remain on PA with the proposed criteria.

New Drugs for Continued PA

• The committee discussed Xenleta and recommended to the department by a unanimous vote that Xenleta remain on PA with the proposed criteria.

• The committee discussed Wakix and recommended to the department by a unanimous vote that Wakix remain on PA with the proposed criteria with the change to the 12th bullet of the initial approval criteria “3 month trial of maximum tolerated dose of modafinil.”

Adjournment

• The meeting was adjourned at approximately 8:05 PM Central Time.